Therapy Management in Patients Treated With Anakinra Due to Recurrent Pericarditis
Serial Cardiac Magnetic Resonance Imaging for Guidance of Therapy Management in Patients Treated With Anakinra Due to Recurrent Pericarditis
Azienda Ospedaliero, Universitaria Ospedali Riuniti
20 participants
Jan 1, 2018
INTERVENTIONAL
Conditions
Summary
To determine the utility of serial cardiac magnetic resonance (CMR) imaging for guidance of therapy management in patients treated with anakinra due to recurrent pericarditis (RP), compared with c-reactive protein (CRP) assay alone.
Eligibility
Inclusion Criteria3
- Adult patients treated with anakinra 100 mg/die if ≥ 18 years old, and
- Pediatric patients treated with anakinra 2 mg/kg/die if \< 18 years old
- Pediatric and adult patients treated with anakinra due to corticosteroid-dependent or not responsive to colchicine or non-steroidal anti-inflammatory drugs (NSAIDs) recurrent pericarditis
Exclusion Criteria2
- Ongoing infection (proved within serology)
- Refuse to participate in the trial
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Anakinra, an IL-1 antagonist, is particularly interesting because it limits the self-sustained pathway of recurrent pericarditis and may reduce the recurrences
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06071156